Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

NCT02055274 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: LY03003
DRUG: Neupro

Sponsor

Luye Pharma Group Ltd.